



UNIVERSIDADE ESTADUAL DE CAMPINAS  
SISTEMA DE BIBLIOTECAS DA UNICAMP  
REPOSITÓRIO DA PRODUÇÃO CIENTÍFICA E INTELLECTUAL DA UNICAMP

**Versão do arquivo anexado / Version of attached file:**

Versão do Editor / Published Version

**Mais informações no site da editora / Further information on publisher's website:**

[https://www.scielo.br/scielo.php?script=sci\\_arttext&pid=S0102-09352015000601539](https://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-09352015000601539)

**DOI: 10.1590/1678-4162-8057**

**Direitos autorais / Publisher's copyright statement:**

©2015 by UFMG/Escola de Veterinária. All rights reserved.

DIRETORIA DE TRATAMENTO DA INFORMAÇÃO

Cidade Universitária Zeferino Vaz Barão Geraldo

CEP 13083-970 – Campinas SP

Fone: (19) 3521-6493

<http://www.repositorio.unicamp.br>

## Subarachnoid injection of ifenprodil and ketamine association improves the anti-hyperalgesic action of ketamine in dogs

[*Injeção subaracnoidea da associação ifenprodil e cetamina melhora a ação anti-hiperalgésica da cetamina em cães*]

E.S. Rondon<sup>1</sup>, C.A.A. Valadão<sup>2</sup>, C.A. Parada<sup>3</sup>

<sup>1</sup>Faculdade de Medicina Veterinária e Zootecnia – Universidade Federal de Mato Grosso do Sul – FAMEZ-UFMS – Campo Grande, MS

<sup>2</sup>Faculdade de Ciências Agrárias e Veterinárias – Universidade Estadual Paulista Júlio de Mesquita Filho – Unesp – Jaboticabal, SP

<sup>3</sup>Instituto de Biologia – Universidade Estadual de Campinas – UNICAMP – Campinas, SP

### ABSTRACT

To test clinically whether a small dose of ifenprodil can enhance the anti-hyperalgesic effect of ketamine in dogs, a prospective randomized cross-over study was done with eight mongrel dogs (weighing  $16.9 \pm 3.7$ kg). Animals received two distinct treatments: ketamine ( $0.3\text{mg kg}^{-1}$ ; KT) and an ifenprodil plus ketamine combination ( $0.03\text{mg kg}^{-1}$  and  $0.3\text{mg kg}^{-1}$ , respectively; IKT). Dogs were anesthetized with propofol ( $5\text{mg kg}^{-1}$  intravenously) and a subarachnoid needle was placed between the 5<sup>th</sup> and 6<sup>th</sup> lumbar vertebrae. Five minutes after subarachnoid injection of KT or IKT, an incision including cutaneous and subcutaneous tissues was made on the common pad of one hind limb and was immediately closed with a simple interrupted suture pattern. The dogs were treated again 20 days later, using the contralateral pad and the opposite treatment. Sedation score (SS), lameness score (LS), heart rate (HR), respiratory rate ( $f_R$ ), and mechanical nociceptive threshold using von Frey filaments, were evaluated before anesthesia and at 1, 1.5, 2, 3, 4, 8, 12, and 24 hours after subarachnoid injection. There were no differences in SS, LS, HR or  $f_R$  between treatments. The intensity of hyperalgesia was higher in KT than in IKT for 24 hours. The anti-hyperalgesic effect of IKT remained without statistical significant difference between 1 and 24 h. Prior subarachnoid administration of ifenprodil enhances the anti-hyperalgesic effect of subarachnoid ketamine in dogs. Ifenprodil can be co-administrated with ketamine to enhance its anti-hyperalgesic effect and to reduce acute post-incisional hyperalgesia without motor impairment and sedation.

Keywords: analgesia, inflammatory pain, NMDA, pain, subarachnoid

### RESUMO

*Com a finalidade de testar se uma dose baixa de ifenprodil pode melhorar a ação anti-hiperalgésica da cetamina em cães, um estudo randomizado prospectivo no formato cross-over foi realizado em oito cães sem raça definida (pesando  $16,9 \pm 3,7$ kg). Os animais receberam dois tratamentos distintos: cetamina ( $0,3\text{mg kg}^{-1}$ ; KT) e a associação de ifenprodil com cetamina ( $0,03\text{mg kg}^{-1}$  e  $0,3\text{mg kg}^{-1}$ , respectivamente; IKT). Os cães foram anestesiados com propofol ( $5\text{mg kg}^{-1}$ , via intravenosa), e uma agulha subaracnoidea foi introduzida entre a quinta e sexta vértebras lombares. Após cinco minutos da injeção subaracnoidea de KT ou IKT, uma incisão abrangendo os tecidos cutâneo e subcutâneo foi realizada no coxim plantar comum de um dos membros pélvicos e imediatamente fechada com um padrão de sutura simples e interrompido. Os cães foram novamente tratados após 20 dias, usando-se o coxim plantar contralateral e o outro tratamento. Os escores de sedação (SS) e claudicação (LS); as frequências cardíacas (HR) e respiratória ( $f_R$ ) e o limiar nociceptivo ao estímulo mecânico, utilizando os filamentos de von Frey, foram avaliados antes da anestesia e uma, uma e meia; duas; três; quatro; oito;*

---

Recebido em 10 de outubro de 2014

Aceito em 14 de julho de 2015

E-mail: itacron@gmail.com

12 e 24 horas após a injeção subaracnoidea. Não foram observadas diferenças significativas em SS, LS, HR ou na  $f_R$  entre os tratamentos. A intensidade da hiperalgesia foi maior em KT que em IKT nas 24 horas. O efeito anti-hiperalgésico de IKT se manteve sem diferença significativa entre os tempos uma hora e 24 horas. A administração prévia de ifenprodil aumentou a ação anti-hiperalgésica da cetamina subaracnoidea em cães. O ifenprodil pode ser coadministrado com cetamina para aumentar seu efeito anti-hiperalgésico e reduzir a hiperalgesia aguda pós-incisional, sem alterações motoras e sedação.

Palavras-chave: analgesia, dor inflamatória, NMDA, dor, subaracnoide

## INTRODUCTION

The NMDA (N-methyl-D-aspartate) receptor controls the cellular permeability to monovalent cations and calcium through a coupled ion channel and is involved with the development of acute neuropathic and inflammatory pain (Ridel and Neeck, 2001).

A functional NMDA receptor is composed of one NR1 subunit and one or more NR2 subunits (A, B, C or D). An NR3 subunit (A or B) can also be found. Activation of the NMDA receptor depends on the removal of a  $Mg^{+2}$  block and, simultaneously, on the interaction of glutamate and glycine at their respective sites of action, NR1 and NR2 (Errenger *et al.*, 2004). It has been reported that opening of the ion channels coupled to NR2A and NR2B subunits results in higher levels of conductance than NR2C and NR2D subunits (Candy *et al.*, 2001). In addition, painful states cause an increase of polyamines in central nervous system (CNS), enhancing the activity of NR2B subunit and its role in nociceptive transmission (Chizh *et al.*, 2001).

Ketamine is a noncompetitive NMDA receptor antagonist widely used to control moderate to severe pain. Its analgesic effect has been demonstrated in rats (Oatway *et al.*, 2003) and in humans (Kvarnström *et al.*, 2003). Ketamine blocks the NR1 subunit (Liu *et al.*, 2001) of NMDA receptor at the internal portion of the ion channel coupled to the receptor, more specifically at its phencyclidine site. In addition, ketamine appears to block NMDA receptor by an allosteric mechanism, at a site within the lipidic portion of the cellular membrane (Orser *et al.*, 1997).

Ifenprodil has been successfully used as an analgesic in several models of rodent neuropathic and inflammatory pain (Xu and Yang, 2006). In dogs, ifenprodil cardiovascular properties were tested (Mizusawa and Sakakibara, 1975) but

until now it is not had been tested in pain models.

Ifenprodil is not structurally related to the conventional NMDA receptor antagonists, and it selectively inhibits the NR2B subunit of NMDA receptor. It appears to competitively interact with the polyamine site, increasing the NR2B subunit sensitivity to blockade of the ion channel by protons, and forcing the agonist-bound NMDA receptor to a conformation with low probability of opening (Mott *et al.*, 1998). It has also been reported that ifenprodil can allosterically interact in a non-competitive manner with the  $Mg^{+2}$  binding site of NR1 subunit (Kew and Kemp, 1998).

In rats, the pre-emptive intrathecal administration of very small doses of ifenprodil, immediately prior to subarachnoid administration of ketamine, significantly enhances the anti-hyperalgesic effect, compared to intrathecal administration of ketamine alone. This combination was shown to be useful to control inflammatory pain with less undesirable systemic effects than ketamine alone (Rondon *et al.*, 2010).

The aim of this study was to investigate if subarachnoid injection of ifenprodil immediately prior to subarachnoid injection of ketamine enhances the anti-hyperalgesic effect of ketamine in dogs subjected to an incision in cutaneous and subcutaneous tissues. We hypothesized that nociceptive mechanical thresholds would be higher when ifenprodil is administered before ketamine subarachnoid injection.

## MATERIALS AND METHODS

All animal experimental procedures and protocols were approved by an Institutional Committee on Animal Research (CEBEA, FCAV/Unesp-Jaboticabal, Processo nº 004990-08).

### Subarachnoid injection...

Eight healthy mongrel dogs (3-5 years, mean±SD weight 16.9±3.7kg), including three females out of gestational, proestrus or estrus periods, were used. Dogs were deemed healthy based on physical examination and laboratory tests (complete blood count, serum aspartate aminotransferase, serum alanine aminotransferase and blood urea nitrogen). The sample size was calculated (Eng, 2003) to minimize the number of animals used. All efforts were made to minimize their discomfort.

Dogs received two distinct treatments: ketamine (0.3mg kg<sup>-1</sup>; KT) or an ifenprodil and ketamine combination (0.03mg kg<sup>-1</sup> and 0.3mg kg<sup>-1</sup>, respectively; IKT). After clipping and aseptic preparation of the lumbosacral region, dogs were anesthetized with propofol (Propofol, Cristália Produtos Químicos e Farmacêuticos Ltda., Brazil) (5mg kg<sup>-1</sup>), administered through an indwelling IV catheter, and anesthesia was maintained with additional doses of this anesthetic as necessary. No endotracheal tube was placed and dogs were maintained without supplemental oxygen. Dogs were positioned in right lateral recumbency with the hind limbs directed cranially. A 22-gauge x 6.35 cm spinal needle (Spinal; Becton Dickinson Ind. Cirúrgicas Ltda., Brazil) was placed into the subarachnoid space between 5th and 6th lumbar vertebrae and the correct needle positioning was confirmed by observation of cerebrospinal fluid draining. Ten percent Ketamine (Francotar, Eurofarma Laboratórios Ltda., Brazil) or 0.1% ifenprodil (Ifenprodil Tartrate Salt, Sigma-Aldrich, USA) followed by a 0.5mL flush of saline solution and

10% ketamine were administered in KT and IKT treatments, respectively. Doses were obtained from previous data in dose-response curves in rats (Rondon *et al.*, 2010) and extrapolated (linear extrapolation by weight) to dogs. The final volume was adjusted to 0.15mL kg<sup>-1</sup> with isotonic saline solution (Cloreto de Sódio 0.9%, Cristália Produtos Químicos e Farmacêuticos Ltda., Brazil). After injection of drugs, the needle was removed and dogs were rotated to sternal recumbency. Five minutes after subarachnoid injection, a 2cm longitudinal incision was made including the cutaneous and subcutaneous tissues of the common pad of a hind limb (randomly selected). The incision was immediately closed with nylon (Nylon Monofilamentar 2-0, Cirumédica S.A., Brazil) suture, using a simple interrupted pattern. Dogs were maintained in sternal recumbency until they were able to stand and walk. After a 20-day washout period, the procedures were repeated on all dogs as described above, using the opposite treatment and the contralateral limb, totaling eight observations per treatment.

Sedation score (SS; Table 1), lameness score (LS; Table 2) (Duque *et al.*, 2004), heart rate (HR), respiratory rate (f<sub>R</sub>), and mechanical nociceptive threshold (MNT) were evaluated before anesthesia and 1, 1.5, 2, 3, 4, 8, 12 and 24 hours after subarachnoid injection. Heart rate and f<sub>R</sub> were determined by thoracic auscultation with stethoscope. All the observations and measures were made in a non-blinded way by the same experimenter.

Table 1. Sedation scoring system

Sedation Score	
Behavior	Score
Alert and walking normally	0
Somnolent, standing with head down and eyes semiclosed	1
Somnolent, laterally or sternally recumbent, responds to calling	2
Somnolent, laterally or sternally recumbent, does not respond to calling	3

Table 2. Lameness scoring system

Lameness Score	
Position	Score
Complete weight bearing	0
Partial weight bearing (standing and walking)	1
Partial weight bearing (standing only)	2
No weight bearing	3

Mechanical nociceptive threshold (MNT) was assessed with von Frey filaments (Touch-Test Sensory Evaluator, North Coast Medical Inc, USA) in ascending order. Each filament was applied at 3-second intervals to four different points (cardinal points) located 3mm away from the incision line. Measurements started by pressing the thinnest filament for 1 second until the nylon bents. The test was then repeated with the next filament until a response (withdrawal movement of limb) was obtained at 3 of the 4 points evaluated. The test was then interrupted and peri-incisional MNT was considered to be the force exerted by the previous thickest filament that did not elicit a response. If no response was obtained with the last filament (446.683g), the evaluation ceased and MNT was considered to be 447g. The magnitude of hyperalgesia was reported as  $\Delta$ MNT (g), which was calculated by subtracting the baseline MNT value (e.g., before spinal injection) from that measured at each time point after incision.

Changes in  $\Delta$ MNT over time, expressed as absolute values; heart rate and respiratory rate data were statistically analyzed using Two-way Repeated Measures ANOVA and Bonferroni post hoc test. Statistical significance was set at  $P < 0.05$  (Graph Pad Software, San Diego, CA, USA). Data are reported as mean $\pm$ SD.

**RESULTS**

Total anesthesia time was 30 minutes. No signs of CNS excitement were observed in any dog at any time point.

Sedation and lameness scores were 0 for the entire duration of the study. Baseline HR values were 101 $\pm$ 14 and 97 $\pm$ 32 beats per minute in KT and IKT, respectively. No significant change in HR over time was seen in either treatment, and no difference between treatments was detected (Table 3).

Table 3. Heart rate (mean $\pm$ SD) before (baseline) and after subarachnoid administration of ketamine (KT) or ifenprodil plus ketamine (IKT) in eight dogs subjected to surgical incision

Treatment	Time (h)	Heart Rate								
		Baseline	1	1.5	2	3	4	6	12	24
KT (n=8)	Mean $\pm$ S			95 $\pm$ 1	94 $\pm$ 1	100 $\pm$ 1	97 $\pm$ 1		102 $\pm$ 1	
	D	101 $\pm$ 14	99 $\pm$ 13	6	5	9	5	93 $\pm$ 14	4	98 $\pm$ 18
IKT (n=8)	Mean $\pm$ S		105 $\pm$ 1	96 $\pm$ 1	87 $\pm$ 1	107 $\pm$ 1	96 $\pm$ 1	100 $\pm$ 1		108 $\pm$ 1
	D	97 $\pm$ 23	3	6	2	2	6	5	89 $\pm$ 8	2

SD = standard deviation

Baseline  $f_R$  was 21 $\pm$ 3 and 27 $\pm$ 8 breaths per minute in the KT and IKT, respectively. No significant change in  $f_R$  over time was seen in

either treatment, and no difference between treatments was detected (Table 4).

Table 4. Respiratory rate (mean $\pm$ SD) before (baseline) and after subarachnoid administration of ketamine (KT) or ifenprodil plus ketamine (IKT) in eight dogs subjected to surgical incision

Treatment	Time (h)	Respiratory Rate								
		Baseline	1	1.5	2	3	4	6	12	24
KT (n=8)	Mean $\pm$ SD	21 $\pm$ 3	22 $\pm$ 6	22 $\pm$ 4	23 $\pm$ 5	23 $\pm$ 5	18 $\pm$ 3	19 $\pm$ 7	21 $\pm$ 3	20 $\pm$ 4
	Mean $\pm$ SD	27 $\pm$ 8	18 $\pm$ 5	24 $\pm$ 4	19 $\pm$ 4	25 $\pm$ 7	24 $\pm$ 5	22 $\pm$ 4	20 $\pm$ 4	22 $\pm$ 5

SD = standard deviation

Mechanical nociceptive thresholds before treatment (baseline) were 396 $\pm$ 31g and 309 $\pm$ 51g in KT and IKT, respectively. The  $\Delta$ MNT calculated after incision was significantly

different between treatments at all time-points (Figure 1). The  $\Delta$ MNT did not change over time in KT and IKT ( $P=0.04$ ).




Figure 1. Time course of anti-hyperalgesic effect induced by combination of ifenprodil (0.03mg kg<sup>-1</sup>) and ketamine (0.3mg kg<sup>-1</sup>; IKT) when compared with ketamine administered alone (0.3mg kg<sup>-1</sup>; KT) in dogs subjected to surgical incision. Drugs were administered (subarachnoid route) five minutes before the surgical incision. The MNT was measured by von Frey filaments and baseline values before surgery were 309g (IKT) and 396g (KT). The symbol\*\*\* means significantly different from KT (P<0.001, Two-way Repeated Measures ANOVA, Bonferroni post hoc test; eight dogs per treatment).

## DISCUSSION

In this study, the subarachnoid injection of ketamine or ifenprodil plus ketamine did not produce signs of CNS excitement, sedation, or motor impairment in any dog. High doses of NMDA receptor antagonists have been reported to cause motor impairment (Boyce *et al.*, 1999; Duque *et al.*, 2004) however subanesthetic doses were administered in this study.

Propofol used for hypnosis in dogs has an anesthetic recovery time between 2 and 4 minutes, in part due to its rapid biotransformation (Morgan and Legge, 1989). Therefore, the first post-surgical evaluation was unlikely to be affected by the short propofol anesthesia. This is supported by the observation that SS did not change significantly from baseline to post-treatment measurements (1 to 24 hours).

The LS remained unchanged over time in both treatments indicating that animals felt comfortable in supporting the hind limb and also did not show motor abnormalities. Painful conditions have been associated with alterations in HR and fR (Grunau *et al.*, 1998; Molony and Kent, 1997). In this study, these variables were not significantly different between treatments. This suggests that neither KT nor IKT had a direct effect on these variables, and that either both treatments were effective for reducing pain associated with cutaneous and subcutaneous incision or the pain produced by those incisions was insufficient to cause alterations in HR and f<sub>R</sub>.

Previous data from our laboratory showed that intrathecal injection of low doses of ifenprodil, administered immediately prior to ketamine, enhances anti-hyperalgesic effect of the latter

drug, compared to each drug administered alone, and prevented the hyperalgesia induced by intraplantar injection of PGE<sub>2</sub> in rats (Rondon *et al.*, 2010). This isobolographic study demonstrated that ifenprodil potentiates the anti-hyperalgesic effect of ketamine, in rats. Based on that, in this present study we clinically demonstrated that ifenprodil (0.03 mg kg<sup>-1</sup>) was effective to significantly enhance the anti-hyperalgesic effect induced by the usual dose of ketamine (Duque *et al.*, 2004).

Ketamine and ifenprodil act at NMDA receptor, which plays an important role in acute and chronic nociception (Oatway *et al.*, 2003; Xu and Yang, 2006). It has been suggested that sensitization of peripheral nociceptor neurons results in continuous release of glutamate in the spinal cord and action of glutamate at NMDA receptors (Parada *et al.*, 2003). The activation of NMDA receptors in spinal cord causes central sensitization (Eide, 2000) in addition to peripheral sensitization (Flossos, 2004). Moreover, a retrograde sensitization of primary sensory neurons can be mediated by release of glutamate and NMDA receptors in the spinal cord (Parada *et al.*, 2003). Finally, inflammatory processes in peripheral tissues may facilitate the activation of NMDA receptors in the spinal cord (Stanfa *et al.*, 1996).

Interestingly, the findings of this study demonstrated that modulation of NMDA receptors by ifenprodil can improve the anti-hyperalgesic action of a known effective dose of ketamine (Duque *et al.*, 2004). The analgesic effects of ketamine appear to occur by the blockade of NMDA receptors when the coupled ion channel is closed (Orser *et al.*, 1997).

It is also important to consider that NMDA NR1 subunit is widely expressed in the spinal cord gray matter; whereas, NMDA NR2B subunit is expressed mainly in laminae I and II, where most nociceptive primary afferents fibers terminate (Nagy *et al.*, 2004). Therefore, NR2B selective antagonists, such as ifenprodil, at least when administered intrathecally, could be more selective in the control of nociception than ketamine (Boyce *et al.*, 1999). The combination of ifenprodil and ketamine, could trigger NR1

blockade mediated by ketamine, selecting NMDA receptors containing NR2B. Therefore, this combination may greatly narrow these pharmacological actions on spinal cord nociceptive systems.

Although we observed that in the IKT, the anti-hyperalgesic effect after 1 h declined during the time, there was no significant statistical difference (Bonferroni post hoc test) until last measure (24 h). In the other hand, KT graphic showed a more linear pattern of effect. Differences in ketamine and ifenprodil pharmacokinetics may have contributed to this finding. However, it remains hypothetical since the pharmacokinetics of ketamine and ifenprodil following subarachnoid administration have not been reported in dogs.

A non-pharmaceutical grade of ifenprodil was used because there is not an injectable commercial form of this drug. However, it is described that ifenprodil has neuroprotective effects (Bath *et al.*, 1996).

In the present study, it was demonstrated that ifenprodil (0.03 mg kg<sup>-1</sup>, subarachnoid) is effective in dogs for use prior to a subanesthetic dose of ketamine (0.3 mg kg<sup>-1</sup>, subarachnoid) to enhance its effect without motor impairment, clinical signs of neurological injury and sedation during, at least, 24 hours after a surgical incision. Similar observations were made in other species and also in dogs. Epidural or intrathecal injections of ketamine were not correlated with neurological injuries in ponies (Doherty *et al.*, 1997) and dogs (Amarpal *et al.*, 1999) but ifenprodil had not been tested yet.

## CONCLUSION

Subarachnoid injection of ifenprodil immediately prior to subarachnoid injection of ketamine enhances the anti-hyperalgesic effect of ketamine in dogs subjected to an incision in cutaneous and subcutaneous tissues.

## ACKNOWLEDGEMENT

This work was supported by grants of CAPES (Brasília, Brazil) and FAPESP (São Paulo, Brazil).

REFERENCES

- AMARPAL, K.; AITHAL, H.P.; SINGH, G.R. *et al.* Preemptive effects of epidural ketamine for analgesia in dogs. *Indian Vet. J.*, v.76, p.300-303, 1999.
- BATH, C.P.; FARRELL, L.N.; GILMORE, J. *et al.* The effects of ifenprodil and eliprodil on voltage-dependent Ca<sup>2+</sup> channels and in gerbil cerebral ischemia. *Eur. J. Pharmacol.*, v.299, p.103-112, 1996.
- BOYCE, S.; WYATT, A.; WEBB, J.K. *et al.* Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localization of NR2B subunit in dorsal horn. *Neuropharmacology*, v.38, p.611-623, 1999.
- CANDY, S.C.; BRICKEY, S.; FARRANT, M. NMDA receptor subunits: diversity, development and disease. *Curr. Opin. Neurobiol.*, v.11, p.327-335, 2001.
- CHIZH, B.A.; HEADLEY, P.M.; TZSCHENTKE, T.M. NMDA receptor antagonists as analgesics: focus on the NR2B subtype. *Trends Pharmacol. Sci.*, v.22, p.636-642, 2001.
- DOHERTY, T.J.; GEISER, D.R.; ROHRBACH, B.W. The effect of high volume epidural morphine, ketamine, and butorphanol on halothane minimum alveolar concentration in ponies. *Equine Vet. J.*, v.29, p.370-373, 1997.
- DUQUE, J.C.M.; VALADÃO, C.A.A.; FARIAS, A. *et al.* Pre-emptive epidural ketamine or S(+)-ketamine in post-incisional pain in dogs: a comparative study. *Vet. Surg.*, v.33, p.1-7, 2004.
- EIDE, P.K. Wind-up and the NMDA receptor complex from a clinical perspective. *Eur. J. Pain*, v.4, p.5-17, 2000.
- ENG, J. Sample size estimation: how many individuals should be studied? *Radiology*, v.227, p.309-313, 2003.
- ERRENGER, K.; CHEN, P.E.; WYLLIE, D.J.A. *et al.* Glutamate receptor gating. *Crit. Rev. Neurobiol.*, v.16, p.187-224, 2004.
- FLOSSOS, A. An introduction to the neurobiology of pain. *Greek E-J. Perioper Med.*, v.2, p.2-10, 2004.
- GRUNAU, R.E.; OBERLANDER, T.; HOLSTI, L. *et al.* Bedside application of the neonatal facial coding system in pain assessment of premature infants. *Pain*, v.76, p.277-286, 1998.
- KEW, J.N.C.; KEMP, J.A. An allosteric interaction between the NMDA receptor polyamine and ifenprodil sites in rat cultured cortical neurones. *J. Physiol.*, v.512, p.17-28, 1998.
- KVARNSTRÖM, A.; KARLSTEN, M.R.; QUIDING, H. *et al.* The effectiveness of intravenous ketamine and lidocaine on peripheral neuropathic pain. *Acta Anaesthesiol. Scand.*, v.47, p.868-877, 2003.
- LIU, H.T.; HOLLMANN, M.W.; LIU, W.H. *et al.* Modulation of NMDA receptor function by ketamine and magnesium: part I. *Anesth Analg.*, v.92, p.1173-1181, 2001.
- MIZUSAWA, H.; SAKAKIBARA, E. [Effects of 2-(4-benzyl-piperidino)-1-(4-hydroxyphenyl)-1-propanol (ifenprodil) on the cardiovascular system in vivo]. *Folia Pharmacol. Jap.*, v.71, p.597-608, 1975.
- MOLONY, V.; KENT, J.E. Assessment of acute pain in farm animals using behavioral and physiological measurements. *J. Anim. Sci.*, v.75, p.266-272, 1997.
- MORGAN, D.W.T.; LEGGE, K. Clinical evaluation of propofol as an intravenous anaesthetic agent in cats and dogs. *Vet. Rec.*, v.124, p.31-33, 1989.
- MOTT, D.D.; DOHERTY, J.J.; ZHANG, S. *et al.* Phenylethanolamines inhibit NMDA receptors by enhancing proton inhibition. *Nat. Neurosci.*, v.1, p.659-667, 1998.
- NAGY, G.G.; WATANABE, M.; FUKAYA, M. *et al.* Synaptic distribution of the NR1, NR2A and NR2B subunits of the N-methyl-D-aspartate receptor in the rat lumbar spinal cord revealed with an antigen-unmasking technique. *Eur. J. Neurosci.*, v.20, p.3301-3312, 2004.
- OATWAY, M.; REID, A.; SAWYNOK, J. Peripheral antihyperalgesic and analgesic actions of ketamine and amitriptyline in a model of mild thermal injury in the rat. *Anesth. Analg.*, v.97, p.168-173, 2003.



ORSER, B.A.; PENNEFATHER, P.S.; MACDONALD, J.F. Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. *Anesthesiology*, v.86, p.903-917, 1997.

PARADA, C.A.; VIVANCOS, G.G.; TAMBELI, C.H. *et al.* Activation of presynaptic NMDA receptors coupled to NaV1.8-resistant sodium channel C-fibers causes retrograde mechanical nociceptor sensitization. *Pharmacology*, v.100, p.2923-2928, 2003.

RIDEL, W.; NEECK, G. Nociception, pain and antinociception: current concepts. *Z. Rheumatol.*, v.60, p.404-415, 2001.

RONDON, E.S.; VIEIRA, A.S.; VALADÃO, C.A.A. *et al.* The improvement of the anti-hyperalgesic effect of ketamine and of its isomers by the administration of ifenprodil. *Eur. J. Pharmacol.*, v.647, p.84-89, 2010.

STANFA, L.C.; MISRA, C.; DICKENSON, A.H. Amplification of spinal nociceptive transmission depends on the generation of nitric oxide in normal carrageenan rats. *Brain Res.*, v.737, p.92-98, 1996.

XU, F.; YANG, J. Antiinflammatory pain effect of ifenprodil administrated subarachnoidly. *Jiangsu Med. J.*, v.32, p.564-566, 2006.